These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
650 related articles for article (PubMed ID: 15994253)
1. Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD. Aliverti A; Rodger K; Dellacà RL; Stevenson N; Lo Mauro A; Pedotti A; Calverley PM Thorax; 2005 Nov; 60(11):916-24. PubMed ID: 15994253 [TBL] [Abstract][Full Text] [Related]
2. Modulation of operational lung volumes with the use of salbutamol in COPD patients accomplishing upper limbs exercise tests. Porto EF; Castro AA; Nascimento O; Oliveira RC; Cardoso F; Jardim JR Respir Med; 2009 Feb; 103(2):251-7. PubMed ID: 18930646 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD. Jensen D; Amjadi K; Harris-McAllister V; Webb KA; O'Donnell DE Thorax; 2008 Jul; 63(7):606-13. PubMed ID: 18250181 [TBL] [Abstract][Full Text] [Related]
4. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Belman MJ; Botnick WC; Shin JW Am J Respir Crit Care Med; 1996 Mar; 153(3):967-75. PubMed ID: 8630581 [TBL] [Abstract][Full Text] [Related]
5. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Beeh KM; Korn S; Beier J; Jadayel D; Henley M; D'Andrea P; Banerji D Respir Med; 2014 Apr; 108(4):584-92. PubMed ID: 24534204 [TBL] [Abstract][Full Text] [Related]
6. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest. Boni E; Corda L; Franchini D; Chiroli P; Damiani GP; Pini L; Grassi V; Tantucci C Thorax; 2002 Jun; 57(6):528-32. PubMed ID: 12037229 [TBL] [Abstract][Full Text] [Related]
7. Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD. Dellacà RL; Pompilio PP; Walker PP; Duffy N; Pedotti A; Calverley PM Eur Respir J; 2009 Jun; 33(6):1329-37. PubMed ID: 19164347 [TBL] [Abstract][Full Text] [Related]
9. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Man WD; Mustfa N; Nikoletou D; Kaul S; Hart N; Rafferty GF; Donaldson N; Polkey MI; Moxham J Thorax; 2004 Jun; 59(6):471-6. PubMed ID: 15170026 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. O'Donnell DE; Laveneziana P; Ora J; Webb KA; Lam YM; Ofir D Thorax; 2009 Mar; 64(3):216-23. PubMed ID: 19052054 [TBL] [Abstract][Full Text] [Related]
11. Bronchodilators accelerate the dynamics of muscle O2 delivery and utilisation during exercise in COPD. Berton DC; Barbosa PB; Takara LS; Chiappa GR; Siqueira AC; Bravo DM; Ferreira LF; Neder JA Thorax; 2010 Jul; 65(7):588-93. PubMed ID: 20627914 [TBL] [Abstract][Full Text] [Related]
12. A pilot study assessing the effect of bronchodilator on dynamic hyperinflation in LAM. Baldi BG; de Albuquerque AL; Pimenta SP; Salge JM; Kairalla RA; Carvalho CR Respir Med; 2013 Nov; 107(11):1773-80. PubMed ID: 24064347 [TBL] [Abstract][Full Text] [Related]
13. Breathing pattern and chest wall volumes during exercise in patients with cystic fibrosis, pulmonary fibrosis and COPD before and after lung transplantation. Wilkens H; Weingard B; Lo Mauro A; Schena E; Pedotti A; Sybrecht GW; Aliverti A Thorax; 2010 Sep; 65(9):808-14. PubMed ID: 20805177 [TBL] [Abstract][Full Text] [Related]
14. Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD. Guenette JA; Raghavan N; Harris-McAllister V; Preston ME; Webb KA; O'Donnell DE Respir Med; 2011 Dec; 105(12):1836-45. PubMed ID: 21917440 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of nebulised and inhaled salbutamol on breathlessness in severe COPD. Poole PJ; Saini R; Brodie SM; Black PN Respir Med; 2005 Mar; 99(3):372-6. PubMed ID: 15733514 [TBL] [Abstract][Full Text] [Related]
16. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658 [TBL] [Abstract][Full Text] [Related]
17. Effect of fluticasone/salmeterol combination on dyspnea and respiratory mechanics in mild-to-moderate COPD. Guenette JA; Webb KA; O'Donnell DE Respir Med; 2013 May; 107(5):708-16. PubMed ID: 23421968 [TBL] [Abstract][Full Text] [Related]
18. Improved respiratory system conductance following bronchodilator predicts reduced exertional dyspnoea. Diba C; King GG; Berend N; Salome CM Respir Med; 2011 Sep; 105(9):1345-51. PubMed ID: 21482091 [TBL] [Abstract][Full Text] [Related]
19. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. O'Donnell DE; Lam M; Webb KA Am J Respir Crit Care Med; 1998 Nov; 158(5 Pt 1):1557-65. PubMed ID: 9817708 [TBL] [Abstract][Full Text] [Related]
20. The role of domiciliary nebulizers in managing patients with severe COPD. Eiser N; Angus K; McHale S Respir Med; 2001 Apr; 95(4):265-74. PubMed ID: 11316108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]